Subsequent Event	9 Months Ended
Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Event	NOTE 13 — SUBSEQUENT EVENT In October 2014, the Company entered into license agreement with CureTech, Ltd. in which it has licensed exclusive worldwide rights to CureTech’s late-stage clinical molecule pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. Under the license agreement, the Company will be responsible for all development, regulatory, and commercialization activities for pidilizumab for all indications, including in oncology. The Company also entered into a manufacturing and supply agreement with CureTech in October, 2014 under which CureTech will manufacture and supply the antibody to the Company over the next three years for clinical development purposes. In addition, the agreement contemplates a guaranty agreement between the Company and CureTech’s largest (53%) shareholder, Clal Biotechnology Industries Ltd. (CBI), with respect to certain obligations of CureTech. The guaranty is subject to approval by CBI shareholders. If approval for the guaranty is not obtained, the Company has the option to terminate both the license agreement and the manufacturing and supply agreement or proceed with such agreements on reduced economic terms (i.e., a reduction of $2.0 million in the upfront payment and 1% from each tier of royalties). The shareholder vote on the guaranty and, thereafter, the Company’s decision to exercise its option to continue to maintain the license are expected in December 2014. Under the terms of the license agreement, and depending on whether the guaranty from CBI is obtained, CureTech would receive an upfront payment of up to $5.0 million from the Company and would also be entitled to payments upon attainment of certain development and regulatory milestones totaling $85.0 million. In addition, CureTech would be eligible to receive sales based milestone payments totaling up to $245.0 million, upon the achievement of certain annual worldwide net sales thresholds, and tiered royalties ranging from 4% to 11% on annual worldwide net sales.

NOTE 13 — SUBSEQUENT EVENT

In October 2014, the Company entered into license agreement with CureTech, Ltd. in which it has licensed exclusive worldwide rights to CureTech’s late-stage clinical molecule pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. Under the license agreement, the Company will be responsible for all development, regulatory, and commercialization activities for pidilizumab for all indications, including in oncology.

The Company also entered into a manufacturing and supply agreement with CureTech in October, 2014 under which CureTech will manufacture and supply the antibody to the Company over the next three years for clinical development purposes. In addition, the agreement contemplates a guaranty agreement between the Company and CureTech’s largest (53%) shareholder, Clal Biotechnology Industries Ltd. (CBI), with respect to certain obligations of CureTech. The guaranty is subject to approval by CBI shareholders. If approval for the guaranty is not obtained, the Company has the option to terminate both the license agreement and the manufacturing and supply agreement or proceed with such agreements on reduced economic terms (i.e., a reduction of $2.0 million in the upfront payment and 1% from each tier of royalties). The shareholder vote on the guaranty and, thereafter, the Company’s decision to exercise its option to continue to maintain the license are expected in December 2014.

Under the terms of the license agreement, and depending on whether the guaranty from CBI is obtained, CureTech would receive an upfront payment of up to $5.0 million from the Company and would also be entitled to payments upon attainment of certain development and regulatory milestones totaling $85.0 million. In addition, CureTech would be eligible to receive sales based milestone payments totaling up to $245.0 million, upon the achievement of certain annual worldwide net sales thresholds, and tiered royalties ranging from 4% to 11% on annual worldwide net sales.